BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23783171)

  • 1. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
    Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
    Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
    Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
    Schmohl M; Gansser D; Moschetti V; Stangier J
    Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
    Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
    Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
    Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
    Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
    Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
    Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
    Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J; Stähle H; Rathgen K; Fuhr R
    Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.
    Dubé C; Douketis JD; Moffat KA; Schulman S; Blais N
    Thromb Res; 2018 Nov; 171():62-67. PubMed ID: 30261356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
    Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring of Oral Thrombin Inhibitor].
    Matsuno K; Usami T; Hatuse M; Shimizu C
    Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
    Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
    Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.